NICE Nod To Alexion’s Soliris May Mean Move Away From Cost Emphasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the drug’s high price and significant budget impact, NICE has recommended Alexion’s Soliris for aHUS, suggesting the U.K. health technology assessment agency is easing its focus on cost.
You may also be interested in...
Alexion’s Costly Soliris For AHUS Raises “Cost Of Life” Issues At NICE
NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.